Payment overview · 2025
General Payments
$421.24
22 reported records · 12 companies
Healthcare provider profile · identity verified
Charles Vance Buckmaster, M.D.
Allopathic & Osteopathic Physicians|General Practice · FOLEY, AL · NPI 1194711382
Verified facts
What the public records show
CMS Open Payments records show Charles Vance Buckmaster, M.D. received $421.24 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.12 | 22.8% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $73.01 | 17.3% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $52.50 | 12.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.02 | 10.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.43 | 6.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.55 | 5.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.10 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.78 | 4.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.48 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.81 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.51 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.93 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $421.24 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $95.56 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.07 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $52.50 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.02 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.43 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 392 | 48 |
| Gabapentin | Gabapentin | 328 | 56 |
| Clonazepam | Clonazepam | 279 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 270 | 34 |
| Pregabalin | Pregabalin | 234 | 42 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 228 | 25 |
| Alprazolam | Alprazolam | 178 | 23 |
| Tramadol Hcl | Tramadol Hcl | 169 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 89 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 69 | 37 |
| Omeprazole | Omeprazole | 69 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 65 | 35 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 49 | 25 |
| Diazepam | Diazepam | 46 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 38 | suppressed |
| Mounjaro | Tirzepatide | 35 | 17 |
| Lisinopril | Lisinopril | 34 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 13 |
| Trazodone Hcl | Trazodone Hcl | 28 | 14 |
| Methadone Hcl | Methadone Hcl | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | 11 |
| Ozempic | Semaglutide | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | 14 |
| Metformin Hcl | Metformin Hcl | 21 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Xtampza Er | Oxycodone Myristate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 11 |
| Meloxicam | Meloxicam | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | 12 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Furosemide | Furosemide | 17 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Losartan Potassium | Losartan Potassium | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $421.24 · 22 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, LOREEV XR, QULIPTA, REPATHA, REXULTI, SUBLOCADE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error